ULTRAGENYX PHARMACEUTICAL INC. Capital Expenditures Incurred but Not yet Paid
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Capital Expenditures Incurred but Not yet Paid of $5.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was -$544.00K.
- ULTRAGENYX PHARMACEUTICAL INC. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $1.57M, a 22.34% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. capital expenditures incurred but not yet paid for the quarter ending 2024-06-30 was -$381.00K.
- ULTRAGENYX PHARMACEUTICAL INC. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $1.28M, a 85.99% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. capital expenditures incurred but not yet paid for fiscal 2025 was $5.00M, a 66.67% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. capital expenditures incurred but not yet paid for fiscal 2024 was $15.00M, a 50.00% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. capital expenditures incurred but not yet paid for fiscal 2023 was $10.00M, a 44.33% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. capital expenditures incurred but not yet paid for fiscal 2022 was $17.96M, a 5.42% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month | Capital Expenditures Incurred but Not yet Paid 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $5.00M 10-K · filed 2026-02-18 | ||||
| 2025-06-30 | -$544.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.02M 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | $1.57M 10-Q · filed 2025-05-07 | ||||
| 2024-12-31 | $15.00M 10-K · filed 2026-02-18 | $693.00K 10-K · filed 2025-02-19 | |||
| 2024-06-30 | -$381.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $899.00K 10-Q · filed 2025-08-06 | $9.47M derived: sum of 3 quarters · filed 2026-02-18 | $4.84M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2024-03-31 | $1.28M 10-Q · filed 2025-05-07 | $9.85M derived: sum of 2 quarters · filed 2026-02-18 | $5.22M derived: sum of 3 quarters · filed 2026-02-18 | $2.14M derived: sum of 4 quarters · filed 2026-02-18 | |
| 2023-12-31 | $8.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $3.94M derived: sum of 2 quarters · filed 2026-02-18 | $863.00K derived: sum of 3 quarters · filed 2026-02-18 | $10.00M 10-K · filed 2026-02-18 | $1.58M 10-K · filed 2024-02-21 |
| 2023-09-30 | -$4.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$7.71M derived: sum of 2 quarters · filed 2024-08-02 | $1.43M 10-Q · filed 2023-11-03 | -$1.04M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-06-30 | -$3.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $6.06M 10-Q · filed 2024-08-02 | $3.59M derived: sum of 3 quarters · filed 2025-02-19 | $1.01M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2023-03-31 | $9.14M 10-Q · filed 2024-05-03 | $6.67M derived: sum of 2 quarters · filed 2025-02-19 | $4.08M derived: sum of 3 quarters · filed 2025-02-19 | $2.32M derived: sum of 4 quarters · filed 2025-02-19 | |
| 2022-12-31 | -$2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$5.06M derived: sum of 2 quarters · filed 2025-02-19 | -$6.82M derived: sum of 3 quarters · filed 2025-02-19 | $17.96M 10-K · filed 2025-02-19 | |
| 2022-09-30 | -$2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$4.35M derived: sum of 2 quarters · filed 2023-11-03 | $20.43M 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | -$1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $23.02M 10-Q · filed 2023-08-04 | |||
| 2022-03-31 | $24.78M 10-Q · filed 2023-05-05 | ||||
| 2021-12-31 | $18.99M 10-K · filed 2024-02-21 | ||||
| 2020-12-31 | $8.52M 10-K · filed 2023-02-17 | ||||
| 2019-12-31 | $10.37M 10-K · filed 2022-02-15 | ||||
| 2018-12-31 | $1.19M 10-K · filed 2021-02-12 | ||||
| 2017-12-31 | $400.00K 10-K · filed 2020-02-14 | ||||
| 2016-12-31 | $147.00K 10-K · filed 2019-02-20 | ||||
| 2015-12-31 | -$355.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | -$379.00K derived: sum of 2 quarters · filed 2018-02-21 | $769.00K 10-K · filed 2018-02-21 | ||
| 2015-09-30 | -$24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $1.12M 10-Q · filed 2015-11-10 | |||
| 2015-06-30 | $1.15M 10-Q · filed 2015-08-14 | ||||
| 2014-12-31 | $171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $50.00K derived: sum of 2 quarters · filed 2017-02-17 | $243.00K 10-K · filed 2017-02-17 | ||
| 2014-09-30 | -$121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $72.00K 10-Q · filed 2015-11-10 | |||
| 2014-06-30 | $193.00K 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |